In March 2023, Triastek had partnered with Boehringer Ingelheim China to explore the
application of Triastek's proprietary Melt Extrusion Deposition (MED®) 3D printing
technology in accelerating the development of the dosage form for new chemical entity (NCE).
Triastek deploys its MED® technology to create multiple prototypes of NCE by exploring
different dose designs and drug release behaviors at speed, ultimately accelerating the R&D
cycle and increasing product development success rates.
In July 2022, Triastek partnered with global pharmaceutical company Eli Lilly to research
and develop 3D printed oral drugs for the gastrointestinal tract. The project leveraged
Triastek's proprietary Melt Extrusion Deposition (MED®) technology to fabricate programmed
drug release profiles to target specific areas of the human digestive system.
In 2022, MilliporeSigma's SAFC Raw Material team collaborated with Triastek on a joint
research project to demonstrate the applicability of the PVA solubility enhancement platform
for 3DP using MED® technology. A particular focus of the project was to achieve the
continuous printing of a poorly soluble drug. The collaboration revealed significant
synergies between Triastek's MED® technology and MilliporeSigma's PVA solubility excipient.
In March 2022, Triastek and Siemens signed a strategic collaboration agreement to provide
digital technologies for the global pharmaceutical industry. Combining Triastek's
industry-leading 3D printing and digital pharmaceutical technologies and Siemens' global
leadership in automation and digitization is expected to lead to innovative and
transformative solutions for the development and manufacturing of pharmaceuticals.
In November 2023, Triastek and Siemens signed a deepening strategic cooperation agreement
while attending CIIE. The two companies will continue to focus on the goal of
"digitalization of the pharmaceutical industry" to jointly develop world-leading digital
pharmaceutical technology and production solutions and promote the digital transformation of
global pharmaceutical companies.
In April 2021, Triastek announced a collaboration about product
development and commercialization with Sperogenix Therapeutics, focusing on the research and
development and commercialization of drugs for rare diseases in China, to jointly develop an
modified new drug T22 for patients with pulmonary hypertension (PAH). Sperogenix
Therapeutics obtained the exclusive commercial rights of T22 in East Asia.